

Media Release

BMS commits to continued innovation and access to breakthrough medicines on 70th anniversary

(AUSTRALIA, Melbourne, 11 December 2025) - Melbourne-headquartered Bristol Myers Squibb Australia (BMSA), a foundational pillar of Australia's life sciences sector since 1955, marked its 70th anniversary last night by highlighting its legacy of delivering more than 380 medicine indication registrations, and reaching 100,000+ new patients annually, at a special event at the Investment Centre Victoria in Melbourne, hosted by The Hon. Danny Pearson, Minister for Economic Growth and Jobs and Minister for Finance.

BMSA's first manufacturing site was opened by Prime Minister Harold Holt in 1967. Today, the company's seven-decade history of shaping Australian health outcomes is being steered by General Manager Owen Smith, a former UK MP, whose unique background in global politics provides a rare perspective on the partnership between industry and government.

"Having viewed healthcare policy from the benches of Parliament in the UK, I have a unique appreciation for what a 70-year partnership between an innovator like BMS and a nation like Australia truly represents," said Mr. Smith.

"It's a legacy that goes far beyond the medicines themselves. It's about sovereign research capability and a robust innovation ecosystem. Today, our Australian team is a global hub for development, running more than 90 active clinical studies, the most in the Asia-Pacific region, which involve 18% of all patients from BMS priority trials across the Asia-Pacific and 5% globally. That is the tangible result of sustained, long-term investment. As we celebrate 70 years, our commitment is to ensure the policy settings are right for Australia to remain a world leader in medical innovation for the next 70."

The company launched its first anti-cancer treatment in the 1960s and launched key treatments for HIV, AIDS, haematological diseases, cardiovascular diseases and cancers in the 1990s. During its history, BMSA's medicines have treated life-limiting and life-changing conditions, in therapeutic areas of oncology, immunology, haematology, cardiovascular, neuroscience, anti-infectives, endocrinology and dermatology.

In recognition of this sizeable contribution, the event brought together political, industry, clinical, and patient advocacy leaders to recognise the company's profound impact, which includes listing over 75 unique medicines across hundreds of indications in the last decade alone.

The 70th-anniversary event was attended by Bristol Myers Squibb's Senior Vice President for the APAC region, Steve Sugino.

"The expertise within the BMS Australia team contributes to our global success," said Mr. Sugino.

"Australia plays an important role in supporting BMS's clinical trials and operations across various APAC markets. By 2030, BMS could have 10 new medicines and at least 30 indications and BMS Australia's ongoing leadership in policy and advocacy, advocating for faster and fairer access to innovative medicines, will help ensure patients in Australia have the opportunity to continue to benefit from the latest advancements."

-ENDS-

About Bristol Myers Squibb™

Bristol Myers Squibb™ is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb™, visit us at [BMS.com](https://www.bms.com) or follow us on [LinkedIn](#), [Twitter](#), [YouTube](#), [Facebook](#) and [Instagram](#).

Further information is available on request from Bristol Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, Level 2, 4 Nexus Court, Mulgrave, VIC, 3170. ™ Trademark. Prepared: November 2025. NO-AU-2500081.

MEDIA ENQUIRIES

Alison Melville, Bristol-Myers Squibb™

E: alison.melville@bms.com | P: 0477 309 012